

THURSDAY 19 NOVEMBER 2015	
08:00-10:00	<b>REGISTRATION &amp; WELCOME COFFEE</b>
10:00-10:15	<b>Introduction and Welcome</b> <b>Annelise Bennaceur-Griscelli</b> <b>Isabelle This Saint Jean, Présidente de l'enseignement supérieur, la recherche et l'innovation</b>
10:15-10:50	<b>Key Lecture</b> <b>George Daley, Harvard</b> <b>iPSC models of human disease</b>
10:50-12:30	<b>Session 1: Mechanisms of reprogramming and genome stability</b> <b>Sponsor: Labex Revive</b> <b>Chairs: Pierre Savatier, Shahraghim Tajbaksh</b> <b>Pablo Navarro-Gil, Revive:</b> Mitotic inheritance of the pluripotency network <b>Manuel Serrano, CNIO, Madrid:</b> Senescence and reprogramming in tissue regeneration and disease <b>Robert Blelloch, UCSF, San Francisco:</b> How to avoid commitment –epigenetic maintenance of pluripotency <b>Louise Laurent, UCSD, San Diego:</b> Causes and Consequences of Genetic Instability in Human Pluripotent Stem Cells <b>Pierre Savatier, Primastem Lyon:</b> Reprogramming pluripotent stem cells toward naïve pluripotency and chimeric competency in humans, monkeys and rabbits.
12:30-14:00	<b>LUNCH / POSTER SESSION 1</b>
14:00-16:00	<b>Session 2: Regulation of ES-iPS differentiation</b> <b>Sponsor: Fluidigm</b> <b>Chairs: Olivier Pourquié, Mark Lynch</b> <b>Mark Lynch, Fluidigm;</b> <b>Raul Mostoslavsky, Harvard Medical School:</b> Stem Cells, Metabolism and Cancer: SIRT6 provides new clues <b>Daniel Aberdam,INSERM - Paris:</b> Pluripotent stem cells as a cellular model for epithelial physiopathology <b>Olivier Pourquié, HSCI IGBMC - Strasbourg:</b> making muscle in vitro to model Duchenne muscular dystrophy
16:00-16:30	<b>COFFEE BREAK</b>

**Pluripotent Stem Cells, Reprogramming and Tissue Engineering, Paris,  
November 19,20<sup>th</sup> 2015- Maison de la Chimie- PARIS**



16:30-18:15	<p><b>Session 3: Technical Challenges</b></p> <p><b>Sponsor: Lonza</b></p> <p>Chairs: Marc Peschanski, Nazim El-Andaloussi</p> <p><b>Nazim El-Andaloussi, Lonza</b> Overcoming Challenges in PSC Culture: Adopt L7TM system from Research to Therapy</p> <p><b>Amit Chandra, Loughborough University:</b> Comparability Protocols Development for Demonstration of Product Equivalence after a Process Change.</p> <p><b>Heiko Zimmermann, Ibmt, Sulzbach:</b> Biobanking of Stem Cells: Improved methods and procedures for pluripotent stem cell preservation, storage stability and validation</p> <p><b>Paula Alves, Ibet, Lisbon:</b> Process Development for Scalable Production of Pluripotent Stem Cells and Cell Based Products</p> <p><b>Mathilde Girard, Istem Evry:</b> Automated production of pluripotent stem cells and their derivatives: new tools for a new era.</p>
19:30	Dinner

FRIDAY 20 NOVEMBER 2015	
08:45-10:20	<p><b>Session 4: Disease modeling and Disease Research</b></p> <p><b>Sponsor: Cellular Dynamics International</b></p> <p>Chairs: Jean Marc Lemaitre, Dominic Hussey</p> <p><b>Dominic Hussey, Cdi:</b></p> <p><b>Chad Cowan,Harvard:</b> Genome Editing: From modeling disease to novel therapeutics.</p> <p><b>Jean Marc Lemaitre, Inserm Montpellier:</b> Premature ageing syndromes tp understand physiological ageing: iPSC as model ?</p> <p><b>Ali Turhan University Paris Sud/Inserm :</b> Patient-derived iPSC: Modeling disease-specific genomic instability.</p>
10:20-10:45	COFFEE BREAK

**Pluripotent Stem Cells, Reprogramming and Tissue Engineering, Paris,  
November 19,20<sup>th</sup> 2015- Maison de la Chimie- PARIS**



10:45-12:30	<p><b>Session 5: iPSC models: from HTS platform to therapeutic molecules</b> Chair: Cécile Martinat</p> <p><b>Alison Ebert, Medical College of Wisconsin,</b> The effect of SMN replacement in SMA iPSCs  <b>Chris Denning, Nottingham :</b> Engineering and phenotyping hPSC–cardiomyocytes to understand genetic disease  <b>Lee Rubin, Harvard:</b> New Insights into Neurodegenerative Disease  <b>Anselme Perrier, Inserm, I-stem, Evry:</b>  Pluripotent stem cells technologies for drug discovery in Huntington's disease: Preventing neuronal loss with REST inhibitors?</p>
12:30-14:30	<b>LUNCH / POSTER SESSION 2</b>
14:30-16:30	<p><b>Session 6: Tissue and cell delivery : from basic research to clinical trials</b> <b>Sponsor: Miltenyi</b></p> <p>Chairs: Annelise Bennaceur Griscelli &amp; Sebastian Knöbel</p> <p><b>Friedrich Metzger, Roche - Basel:</b> Development of highly selective SMN2 splicing modifiers to find a therapy for spinal muscular atrophy  <b>Philippe Menasché, University Paris Descartes, Inserm:</b> Embryonic stem cell–derived cardiac progenitors for heart repair: A translational experience  <b>Peter Coffey, UC London:</b> Stemming Vision Loss Using Human Embryonic Stem Cells  <b>Marc Turner, CRM Edinburgh:</b> Challenges in establishment of a Global iPSC Haplobank</p>